Clinical Trials Browser

Moderate Hepatic Impairment × 90 days × Clear all

NCT07343960 2026-05-20

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Phase 1 Recruiting

Moderate Hepatic Impairment